What happened in this Health story?

A new analysis finds nearly 40% of FDA advisory committee meetings over 20 years included patient or consumer representatives with active ties to pharma-funded advocacy groups, and most of those ties went undisclosed during the proceedings.

What is a key fact in this story? (1)

**An analysis published in Health Affairs Scholar** found that nearly 40% of FDA advisory committee meetings over a recent 20-year period included a patient or consumer representative with active ties to an advocacy group funded by pharmaceutical companies.

What is a key fact in this story? (2)

**Several FDA advisory committees** saw the share of pharma-funded representatives exceed 50%, according to the same analysis.

📎 SkimNews has covered FDA 83+ times · see the file →

FDA: 40% of Advisory Meetings Had Pharma-Linked Patient Reps — SkimNews

By STAT News · Summarized & edited by Kapil Samant · 2026-10-13

Get the Health newsletter

Daily health & science — research, biotech, public health, the studies worth knowing. Free.

An analysis published in Health Affairs Scholar found that nearly 40% of FDA advisory committee meetings over a recent 20-year period included a patient or consumer representative with active ties to an advocacy group funded by pharmaceutical companies.
Several FDA advisory committees saw the share of pharma-funded representatives exceed 50%, according to the same analysis.
More than one in 10 FDA advisory committee meetings included a representative affiliated with an organization that received funding from the drugmaker whose medicine was being reviewed by the committee.
Most of these organizational ties were not disclosed at the meetings, raising questions about voting behavior, the analysis noted.
The FDA has well-established conflict-of-interest policies for its scientific advisory committee members, but policies for patient and consumer representatives are not as well developed—particularly regarding industry funding of advocacy groups whose members sit on committees.

Why it matters: With more than one in 10 advisory meetings featuring a representative tied to the very drugmaker under review—and most ties going undisclosed—the FDA faces pressure to close a conflict-of-interest gap that could shape votes on new drug approvals. Patient voices carry weight in advisory decisions, and undisclosed pharma funding undermines the transparency that patients and regulators depend on.